The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 194 participants.

Also called NCT02521181

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose other
Phase
Phase 3
Enrolled
  • 194 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02521181
Other papers using this trial's data
  • Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial Journal of the American Society of Nephrology : JASN, 2024-01-01 DOI, PubMed 38170601, PMC10786609 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02521181. Randomized; triple masking; primary purpose other. Start 2015-10 (actual); primary completion 2018-01 (actual). Results posted on 2020-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Acronym
BASE
Intervention (Drug)
Lower Dose Sodium Bicarbonate
Intervention (Drug)
Higher Dose Sodium Bicarbonate
Intervention (Drug)
Placebo
Lead sponsor
Jennifer Gassman, PhD (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)
Collaborator
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct02521181
Content hash
c465ed8ed67b677ba6b77a33cfe08842faed6f19a20c2d9823b6fd5d53809357